The FDA approved tenecteplase (TNKase) for adult stroke patients, Genentech announced on Monday. A clot-dissolving tissue ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a ...

Ascension Wisconsin recently honored Racine paramedics and the Ascension All Saints Hospital Emergency Department for their ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

The analysis found: Stroke survivors were 44% more likely to have an excellent outcome (modified Rankin score 0-1) after 90 days if they received the tenecteplase injection and standard care after ...

Get Instant Summarized Text (Gist) Intra-arterial tenecteplase administered after successful thrombectomy in patients with large vessel occlusion between 4.5 and 24 hours post-onset increases the ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...